

Network Guideline for Use of Aranesp

| DOCUMENT TYPE | : | | |
|---|--|---------------------|----------------------------------|
| Lancashire and So | uth Cumbria Cancer Alliance | | |
| DOCUMENT TITLE: | | VERSION NUMBER: 3.0 | |
| Lancashire & South Cumbria Cancer Network Guideline for Use of Aranesp | | | |
| | | STATUS: | |
| | | Ratified | |
| SCOPE: | | CLASSIFICATION: | |
| All Staff involved with SACT | | Departmental | |
| AUTHOR: | JOB TITLE: | Chair: | JOB TITLE: |
| David Eaton | Chemotherapy CRG Chair/ Consultant Oncologist | Dr David Eaton | Consultant Medical Oncologist |
| VALIDATED BY: | | DATE: | |
| LSCCA SACT Clinical Reference Group | | 22 February 2023 | |
| This policy has been written in context of National policy with acknowledgement to the Northern Cancer Alliance Chemotherapy administration policy as a | | | |
| reference. | | | |
| (NOTE: Review dates may alter if any significant | | REVIEW DATE: | |
| changes are made). | | 22 February 2025 | |

